Gilead Sales Double on $1,000 Hepatitis C PillsBy
It turns out you can make real money selling $1,000 pills. That’s what Gilead Sciences discovered in the quarter since the debut of Sovaldi, its hepatitis C treatment that has drawn attention for both its advances over existing therapies and its high price tag.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.